RAPPRapport Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Rapport Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAPP본 종목 | $2.0B#8 | — | 4.8x#8 | — | — | -42.4%#10 | — | -26.4%#8 | — | — | 61.6%#8 | — |
| PVLA | $2.2B#1 | — | 10.3x#13 | 52.4x#11 | 65.3%#5 | -139.3%#11 | -90.2%#7 | -19.2%#7 | — | — | 175.5%#2 | — |
| PBH | $2.2B#3 | 13.0x#1 | 1.1x#2 | 2.0x#4 | -4.3%#12 | -11.3%#9 | 28.4%#1 | 9.9%#1 | 5.9%#1 | 4#1 | -27.4%#14 | — |
| TRVI | $2.2B#2 | — | 6.9x#10 | — | — | 10.7%#8 | — | -13.3%#5 | — | — | 94.0%#4 | — |
| SRPT | $2.2B#4 | — | 1.4x#3 | 1.2x#3 | 4.3%#10 | -403.3%#14 | -37.5%#5 | -46.7%#10 | -73.0%#5 | — | 21.5%#10 | — |
| ZBIO | $2.2B#5 | — | 8.8x#12 | 217.6x#12 | 100.0%#4 | -140.6%#12 | -3830.6%#12 | -152.9%#14 | -296.6%#7 | — | 74.7%#6 | — |
| BHC | $2.1B#6 | — | — | 0.2x#1 | 6.7%#9 | 441.3%#1 | 17.7%#2 | — | 3.6%#2 | — | -2.1%#11 | 16.6%#1 |
| NUVB | $2.1B#7 | — | 8.4x#11 | 34.0x#8 | 699.0%#2 | 64.0%#3 | -338.7%#10 | -80.6%#12 | -87.4%#6 | — | 85.7%#5 | — |
| AGIO | $2.0B#9 | — | 2.0x#5 | 37.6x#9 | 48.0%#6 | -161.3%#13 | -873.9%#11 | -40.3%#9 | — | — | -6.4%#12 | — |
| ZYME | $2.0B#11 | — | 24.5x#14 | 18.6x#7 | 38.9%#7 | 33.9%#5 | -87.3%#6 | -100.9%#13 | — | — | 74.5%#7 | — |
| BHVN | $2.0B#10 | — | 162.9x#15 | — | — | 12.7%#7 | — | -6045.0%#15 | — | — | -10.5%#13 | — |
| PRGO | $1.9B#14 | — | 0.7x#1 | 0.4x#2 | -2.8%#11 | -729.7%#15 | -26.4%#4 | -56.7%#11 | -20.9%#3 | 4#1 | -31.4%#15 | 8.6%#2 |
| SEPN | $1.9B#13 | — | 4.8x#7 | 40.5x#10 | 4174.5%#1 | 31.9%#6 | -148.6%#9 | -12.6%#4 | — | — | 176.5%#1 | — |
| STOK | $1.9B#12 | — | 5.4x#9 | 10.1x#5 | 404.5%#3 | 92.3%#2 | -11.2%#3 | -2.0%#3 | — | — | 27.3%#9 | — |
| XNCR | $1.8B#15 | — | 3.6x#6 | 14.6x#6 | 13.7%#8 | 60.5%#4 | -141.4%#8 | -18.3%#6 | -31.5%#4 | — | 164.9%#3 | — |
| KLRA | $1.7B#16 | — | 1.5x#4 | — | — | — | — | 0.0%#2 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice